Compare Amgen, Inc. (AMGN) vs Crowdstrike Holdings Inc (CRWD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Crowdstrike Holdings Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Crowdstrike Holdings Inc trades at $187.42 (market cap $190.60B). The key difference: Amgen, Inc. and Crowdstrike Holdings Inc are close in size by market cap, and Amgen, Inc. pays a 2.77% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals.
| AMGN | CRWD | |
|---|---|---|
Market Cap | $196.12B | $190.60B |
Sector | Health | Technology |
52-Week High | $388.16 | $199.38 |
52-Week Low | $271.18 | $87.56 |
Enterprise Value | $241.41B | $186.87B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CrowdStrike (CRWD) trades at $187.18, down 5.66% in the last session, following its recent 4-for-1 stock split. The stock exhibits a bullish technical trend with strong moving average signals, though RSI levels suggest overbought conditions. Fundamentally, the company shows robust revenue growth, reaching $3.95 billion in 2025, and has beaten earnings estimates for three consecutive quarters. However, valuation multiples remain elevated with a P/E of 765.02, and net income margins are negative. Analyst sentiment is overwhelmingly positive, with 76% recommending a buy.
The outlook for CRWD is supported by strong demand in AI-driven cybersecurity, but high valuation and intense competition pose risks. Revenue growth acceleration and market leadership in zero-trust security present opportunities, though profitability challenges and premium pricing require careful monitoring. The consensus price target of $184.40 suggests limited near-term upside from current levels, indicating a balanced risk-reward profile for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →
